APP Receives Expedited Approval for the First and Only Generic Cefotetan Disodium for Injection

Abraxis Pharmaceutical Products (APP), the hospital-based business of Abraxis BioScience, Inc., announced the approval from the U.S. Food and Drug Administration (FDA) to market Cefotetan Disodium for Injection, the generic equivalent of AstraZeneca's Cefotan.
American Digital Networks